Vycor Medical to Unveil VBAS Product Line Extension and Prototypes at CNS 65th Annual Meeting in New Orleans, September 26-30, 2015

BOCA RATON, Florida, September 25, 2015 /PRNewswire/ --

Vycor Medical, Inc. ("Vycor") (OTCQB: VYCO), a provider of innovative and superior surgical and therapeutic solutions, will introduce its ViewSite™ Brain Access System (VBAS) product line extension and prototypes at the 2015 Congress of Neurological Surgeons (CNS) Annual Meeting. The event will be held at Ernest N. Morial Convention Center in New Orleans September 26-30, 2015.

Attendees may visit the company's booth (#611) to learn about its two new ViewSite TC model devices that are half the diameter of VBAS smallest devices. The devices were developed in close collaboration with a leading neurosurgeon, who identified a need for a much smaller VBAS than those currently available to allow less invasive surgery yet still enable the use of instruments such as endoscopes. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles. The company expects the devices to be commercially available in the fourth quarter of this year.

Peter Zachariou, CEO of Vycor, commented: "The VBAS product line extension allows us to better address under-served neurosurgical needs in the market and is consistent with our stated objective of adding new product variations to our core VBAS product line. Given the devices' extremely small dimensions and smooth shape, we believe the product features represent a significant step forward in minimally invasive brain access and retraction. We see our two new devices helping us address an estimated 25,000 procedures in the U.S. which were previously un-addressable by Vycor's existing VBAS product line."

Vycor will also showcase at its booth a finalized pre-manufacturing prototype of a set of four VBAS devices designed to be integrated with selected Image Guided Systems (IGS). Management strongly believes that the existing VBAS rigid structure lends itself well to being incorporated into the increasing trend of IGS surgery. The products being displayed were developed in conjunction with input from both a leading neurosurgeon and a strategic company that is a leader in the image guidance space. The company plans to launch the products in the second half of 2016.

In addition, neurosurgeons from the Department of Neurological Surgery, Weill Cornell Medical College, New York-Presbyterian Hospital, New York will discuss at the Vycor booth the clinical advantages of using VBAS. Management believes that continued high quality clinical data supporting the superiority and benefits of its VBAS product line over traditional retractors will help accelerate its adoption and help make it the future standard of care.

The VBAS was selected to be on the cover of the March edition of the prestigious Journal of Neurosurgery (JNS). Founded in 1944, the Journal of Neurosurgery is recognized by neurosurgeons and related medical specialists worldwide for its authoritative and cutting-edge clinical articles, laboratory research papers, case reports, literature reviews, technical notes, book reviews and more. The Journal of Neurosurgery is cited more often than any other journal dedicated to the field of neurosurgery. In total, there have been five peer reviewed clinical papers published on VBAS in 2015 alone. VBAS is now approved in over 200 hospitals in the U.S. and the number continues to grow. To date, more than 10,000 surgeries have utilized VBAS.

About CNS Annual Meeting 

The CNS Annual Meeting is the premier forum for exploring controversial and hot-button issues impacting the neurosurgical specialty and for learning about the most cutting-edge procedures, approaches, and technologies in the field. For more information about CNS annual meeting, visit http://www.cns.org/annual-meeting-2015.

About Vycor Medical, Inc. 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and full regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU - Class III), Korea and Japan and is seeking or has partial regulatory approvals in India, Russia, Taiwan and Vietnam. For an overview of Vycor Medical's VBAS, see VBAS Video.

NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight as a result of stroke, or brain injury. NovaVision's family of therapies both restore and compensate for lost vision. NovaVision's VRT is the only medical device aimed at the restoration of vision lost as a result of neurological damage which has FDA 510(k) clearance to be marketed in the U.S. NeuroEyeCoach is a compensation therapy registered in the US as a Class I 510(k) exempt device, VRT and NeuroEyeCoach are highly complementary and provided to patients in an Internet-delivered suite, to ensure broad benefits to patients. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, visit http://www.vycormedical.com, http://www.vycorvbas.com or http://www.novavision.com.    

Investor Relations:
Liolios Group, Inc.
Ronald A. Both
Tel 1-949-574-3860
[email protected]

SOURCE Vycor Medical, Inc.